focus -WSS

focus

author：focus 2025-09-27 23:32:53 - browse：9

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Roche drug slashes death risk in early

Wikipedia

WSS

Readout LOUD podcast: Live from the 2023 STAT Summit

Sanofi seeks simpler, safer CRISPR sickle cell cure

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Google and Epic fight stronger regulation of AI in health care

Why a market frenzy over new weight loss drugs defies logic

Cosmetics set for new safety regulation. Why the industry is on board

focus

focus

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

A public scorecard can help hold safety

After affirmative action ruling, medical educators look to 'holistic review'

AI can’t replace a physician’s gut feeling

After affirmative action ruling, medical educators look to 'holistic review'

In early work, researchers turn to CRISPR to treat Alzheimer's

Alkermes shareholders re

STAT Summit: The economic case for universal basic health care

Cancer drug shortages should be causing more outrage

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Wikipedia

Google and Epic fight stronger regulation of AI in health care

STAT Summit: Meghan O’Rourke on making chronic illness visible

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Health tech investors get more selective as pandemic boom fades

Health tech investors get more selective as pandemic boom fades

WHO calls for emergency meeting on new China virus, as cases spread

focus

Wikipedia

leisure time

knowledge